About Experimental Therapeutics

L.Lanier Program Leader Pamela Munster, MD
L.Fong Program Co-Leader Charles S. Craik, PhD

The Experimental Therapeutics Program includes 43 members from 16 academic departments in the UCSF School(s) of Dentistry, Medicine, and Pharmacy. The overarching goal of the Program is to bring together basic cancer biologists and physician scientists to discover and test novel compounds and treatment strategies for cancer.

The Experimental Therapeutics Program conducts research under four main themes:

  • Theme 1: Targeting Signal Transduction Pathways
  • Theme 2: Targeting DNA Replication and Genome Integrity
  • Theme 3: Angiogenesis and Apoptosis
  • Theme 4: Genetic Determinants of Sensitivity and Resistance

The wide range of expertise of the Program members will mutually enrich and complement the discoveries of individual investigators with the overall Program goal being to accelerate the transition from drug discovery to the approval of more effective and less toxic drugs for patients with cancer. Research in the Program spans a breadth of areas, including drug discovery, cell signaling, molecular pathology, bioimaging, and pharmacogenomics, as well as clinical and population science.

The Experimental Therapeutics Program capitalizes on the synergy between multiple programs and a dynamic, Early Phase Clinical Trials Unit. Program Members have wide-ranging interests and expertise in basic studies including drug discovery and preclinical testing to technology development and early phase clinical trials. Due to the dual membership of several members in other Programs in the Center, there is an easy transition from an early phase clinical trial to disease-specific phase II trials in the Breast Oncology, Prostate Cancer, Hematopoietic Malignancies, and Neurologic Oncology Programs. Similarly, the dual membership of many of the basic scientists fosters wide-ranging collaborations across many scientific discoveries and facilitates the rapid transition into clinical trials.